NCT05029102RecruitingPhase 2
TAS-102 Combined With Anlotinib in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments (THALIA): a Prospective Single-arm Phase II Study
Zhejiang University1 site in 1 country45 target enrollmentStarted: September 1, 2021Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- Progression Free Survival
Study Overview
Brief Summary
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years, ≤75 years
- •Histologically confirmed gastric cancer with distant metastasis
- •Progression on ≥ 2 lines of prior standard chemotherapy
- •Patients can swallow pills normally
- •Expected overall survival ≥6 months
- •Blood routine: no blood transfusion or blood products usage within 14 days, G-CSF or other hematopoietic stimulator was not used. WBC counts > 3000/µl，Absolute neutrophil count (ANC) ≥ 1500 cells/µl，Platelet count ≥ 100,000/µl，Hemoglobin ≥ 9.0 g/dL.
- •AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum bilirubin ≤ 1.5 x ULN，creatinine<ULN
- •Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN
- •Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment;
- •Informed consent has been signed.
Exclusion Criteria
- •Active bleeding within 3 months; Occurrence of arterial/venous thrombosis within 6 months; Hereditary or acquired bleeding (e.g., clotting dysfunction) or thrombotic tendencies; Full dose oral or injectable anticoagulants or thrombolytic drugs for therapeutic purposes are currently being used or have been used recently (10 days prior to the commencement of study treatment); Surgery (except for biopsy) was performed within 4 weeks prior to the study or the surgical incision was not fully healed; Aspirin (> 325 mg/ day) or dipyridamole, ticlopidine, clopidogrel, and silotazole are currently being used or have recently been used (10 days prior to the study).
- •Certain or suspected brain metastases.
- •Patients who have received prior therapy of any study drug;
- •Serious uncontrolled systemic diseases, such as severe active infections;
- •A person is known to be infected with the immunodeficiency virus (HIV) or known to be HIV-positive;
- •Patients have suffered from other malignancies in the past 5 years except cervical carcinoma in situ or basal cell carcinoma of the skin
- •Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA >500 IU/mL) or active HCV carriers with HCV RNA can be detected. Remarks: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA < 500 IU/mL) may be enrolled
- •Anti-infective therapy was not discontinued 14 days before the study;
- •A prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia, and symptomatic interstitial lung disease or the presence of active pneumonia on a chest CT scan within 4 weeks prior to the study.
- •Patients have a history of intestinal obstruction within six months. Patients with incomplete obstruction syndrome of ileus at the time of initial diagnosis may be enrolled in the study if they have received definitive (surgical) treatment to resolve the symptoms, as assessed by the investigator.
- •Patients have high blood pressure that cannot be well controlled by antihypertensive medication (systolic ≥140 mmHg or diastolic ≥90 mmHg)
- •Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein >1.0g;
- •Known to be allergic to any study drug;
- •Patients have participated in other drug clinical studies within 4 weeks before enrollment;
- •Lactating women
- •According to the judgment of the researcher, the patient may have other factors that may affect the results of the study or cause the study to be terminated, such as alcohol abuse, drug abuse, other serious diseases (including mental diseases) requiring combined treatment. Patients have severe laboratory abnormalities, which will affect the safety of the patient.
Arms & Interventions
TAS-102 and Anlotinib
Experimental
TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
Intervention: TAS 102 (Drug)
TAS-102 and Anlotinib
Experimental
TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
Intervention: Anlotinib (Drug)
Outcomes
Primary Outcomes
Progression Free Survival
Time Frame: 4 months
The time elapsed between treatment initiation and tumor progression
Secondary Outcomes
- Overall Response Rate(2 months)
- Overall Survival(9 months)
Investigators
Weijia Fang, MD
Director of Medical Oncology
Zhejiang University
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric CancerGastric Cancer Adenocarcinoma MetastaticNCT06711471LIN YANG31
Unknown
Phase 2
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05266820Fujian Cancer Hospital120
Withdrawn
Phase 2
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)Gastrointestinal Stromal TumorsNCT02342600Sarcoma Alliance for Research through Collaboration
Unknown
Not Applicable
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric CancerAdvanced Gastric CancerNCT03255811DongMa40
Completed
Phase 2
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerStomach NeoplasmsNeoplasms MetastasisERBB2 Gene AmplificationNCT02004769Sun Yat-sen University67